Vemurafenib and cobimetinib‐induced toxic epidermal necrolysis in a patient with metastatic melanoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Vemurafenib and cobimetinib‐induced toxic epidermal necrolysis in a patient with metastatic melanoma

Published:2019-12-11 Issue:1 Volume:33 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Poduje Sanja¹,Brozić Jasmina M.²,Prkačin Ivana¹,Delaš Aždajić Marija¹^ORCID,Goren Andy³^ORCID

Affiliation:

1. Department of Dermatology and VenerologySestre milosrdnice University Hospital Center Zagreb Croatia

2. Department of Oncology and Nuclear MedicineSestre milosrdnice University Hospital Center Zagreb Croatia

3. Department of DermatologyApplied Biology, Inc. Irvine California

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.13174

Reference15 articles.

1. The role of BRAF V600 mutation in melanoma

2. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

3. Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds

4. Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

5. BRAF and MEK inhibition in melanoma

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stevens-Johnson Syndrome and Severe Anaemia: A Case of Toxicity Induced by Vemurafenib plus Cobimetinib following Pembrolizumab for Metastatic Melanoma;Acta Dermato-Venereologica;2022-02-22

2. Chimeric antigen receptor T-cell therapy for melanoma;Expert Review of Clinical Immunology;2021-01-31

3. Targeting kinases with thymoquinone: a molecular approach to cancer therapeutics;Drug Discovery Today;2020-12

4. Cobimetinib/vemurafenib;Reactions Weekly;2020-12

5. Systematic review of BRAF/MEK inhibitors‐induced Severe Cutaneous Adverse Reactions (SCARs);Journal of the European Academy of Dermatology and Venereology;2020-09-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3